Alnylam Pharmaceuticals Inc. held its 2025 Annual Meeting of Stockholders on May 8, 2025. During the meeting, several proposals were presented and approved by the stockholders. The proposals included the amendment to the company's Restated Certificate of Incorporation to allow for officer exculpation, the approval of the Second Amended and Restated 2018 Stock Incentive Plan, and the ratification of PricewaterhouseCoopers LLP as the independent auditors for the fiscal year ending December 31, 2025. Additionally, the stockholders re-elected four Class III directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.